VentureBeat

Posts Tagged ‘inv:BDC-Capital’

Protiva, a Vancouver, B.C.-based developer of drugs based on the new technology of RNA interference, raised $3.3 million in debenture financing. Investors included GrowthWorks Capital, BDC Capital, the Canadian Medical Discoveries Fund and Kinetic Capital.

Protiva is currently embroiled in litigation against two other biotechs, including Sirna Therapeutics, another RNAi company acquired by Merck last December, and Tekmira Pharmaceuticals.

Top Stories

Recent Comments

Powered by Disqus

Recent Guest Columnists

Job Board

Links

Venturebeat Writers

  • For advertising, contact .
  • Log in

Font Size

Kleer, a Cupertino, Calif. company that says it can provide better audio quality with less power consumed for wireless short-range transmission, has raised a large $28 million funding, its second. Portable media like MP3 players as well as in-home broadcasting are the markets that Kleer is targeting, and the company is also considering international [...]

More ...

Vaperma is a Quebec City, Canada based company that makes dewatering systems for ethanol producers.
Water is a by-product of ethanol production, and must be removed before the product is finished. Vaperma’s specialized membranes can selectively drain the water away, a method the company says is cheaper than distillation columns or chemical dryers.
The CDN $21.5 million [...]

More ...